ADMA Biologics to Report First Quarter 2022 Financial Results on May 11, 2022
May 04 2022 - 7:00AM
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an
end-to-end commercial biopharmaceutical company dedicated to
manufacturing, marketing and developing specialty plasma-derived
biologics, today announced that it will report financial results
for the first quarter ended March 31, 2022 on Wednesday, May 11,
2022, after the U.S. financial markets close. ADMA’s management
team will host a live conference call and audio webcast on that
date at 4:30 p.m. ET to discuss its financial results and other
Company updates.
To access the conference call, please dial (855) 884-8773
(local) or (615) 622-8043 (international) at least 10 minutes prior
to the start time and refer to conference ID 1783606. A live audio
webcast of the call will be available under “Events & Webcasts”
in the investor section of the Company’s website,
https://ir.admabiologics.com/events-webcasts. An archived webcast
will be available on the Company’s website approximately two hours
after the event.
About ADMA Biologics, Inc.
(ADMA)
ADMA Biologics is an end-to-end commercial
biopharmaceutical company dedicated to manufacturing, marketing and
developing specialty plasma-derived biologics for the treatment of
immunodeficient patients at risk for infection and others at risk
for certain infectious diseases. ADMA currently manufactures and
markets three United States Food and Drug Administration
(FDA)-approved plasma-derived biologics for the treatment of immune
deficiencies and the prevention of certain infectious diseases:
ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for
the treatment of primary humoral immunodeficiency (PI); BIVIGAM®
(immune globulin intravenous, human) for the treatment of PI; and
NABI-HB® (hepatitis B immune globulin, human) to provide enhanced
immunity against the hepatitis B virus. ADMA manufactures its
immune globulin products at its FDA-licensed plasma fractionation
and purification facility located in Boca Raton, Florida. Through
its ADMA BioCenters subsidiary, ADMA also operates as an
FDA-approved source plasma collector in the U.S., which provides a
portion of its blood plasma for the manufacture of its products.
ADMA’s mission is to manufacture, market and develop specialty
plasma-derived, human immune globulins targeted to niche patient
populations for the treatment and prevention of certain infectious
diseases and management of immune compromised patient populations
who suffer from an underlying immune deficiency, or who may be
immune compromised for other medical reasons. ADMA has received
U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and
10,259,865 and European Patent No. 3375789 related to certain
aspects of its products and product candidates. For more
information, please visit www.admabiologics.com.
COMPANY CONTACT: Skyler
BloomSenior Director, Business Development & Corporate Strategy
| 201-478-5552 |sbloom@admabio.com
INVESTOR RELATIONS
CONTACT:Michelle Pappanastos Senior Managing Director,
Argot Partners | 212-600-1902 | michelle@argotpartners.com
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Sep 2023 to Sep 2024